BDX vs NAGE: fair value comparison
Becton, Dickinson and Company and Niagen Bioscience, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, NAGE currently sits closer to the top of our discount ranking. NAGE carries the stronger quality grade.
| BDX | NAGE | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $177.85 | $3.13 |
| 12-month range | $145.33–$201.91 | $3.13–$7.89 |
| Sector rank | #50 of 113 Healthcare | #47 of 113 Healthcare |
| Quality grade | D | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Declining | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: BDX fair value analysis · NAGE fair value analysis